This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): topotecan hydrochloride
Description: Hycamtin (topotecan hydrochloride) is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I-inhibitory activity. Topo-I is involved in cell division of both normal and cancer cells. Treatment with Hycamtin damages DNA, which results in the death of dividing cancer cells.
GlaxoSmithKline no longer reports revenues for Hycamtin as of Q1 2012.
GlaxoSmithKline and Novartis
In April 2014, GSK and Novartis entered into a sale agreement under which GSK has agreed to sell, upon completion of the Transaction, the rights to GSKs currently marketed oncology portfolio, related R&D activities and its AKT inhibitor currently in development as well as to grant Novartis preferred partner rights for future commercialisation of GSK oncology products for an aggregate cash consideration of $16 billion. Up to $1.5 billion of this cash consideration depends on the results of the COMBI-d trial, a Phase III study evaluating the safety and efficacy of the combination of Tafinlar (BRAF) and Mekinist (MEK) versus BRAF monotherapy in patients with unresectable or metastatic melanoma.
GSK's marketed Oncology portfolio comprises the rights to GSK's currently marketed oncology assets (Votrient, Arzerra, Promacta/Revolade, Tykerb/Tyverb, Tafinlar,...See full deal structure in Biomedtracker
Additional information available to subscribers only: